Adding Chemotherapy to Osimertinib Improves PFS in EGFR-Mutant, Advanced NSCLC
Osimertinib and chemotherapy is more effective than osimertinib alone as first-line treatment for patients with EGFR-mutant, advanced NSCLC, phase 3 data suggest.
Diagnosis & Disease Information
Patritumab Deruxtecan Deemed Effective in Resistant, EGFR-Mutant NSCLC
Patritumab deruxtecan (HER3-DXd) is effective in patients with previously treated, EGFR-mutant NSCLC, a phase 2 study suggests.
MARS 2: Chemo Alone May Be Superior to Surgery Plus Chemo in Mesothelioma
Chemotherapy alone may produce better outcomes than surgery plus chemotherapy in patients with mesothelioma, the MARS 2 trial suggests.
Adagrasib Shows “Durable Clinical Benefit” in Advanced KRAS-Mutant NSCLC
Adagrasib has shown durable clinical activity in patients with advanced KRASG12C-mutant NSCLC, according to updated results from the KRYSTAL-1 trial.
First-Line Benmelstobart Regimen Produces Longest PFS, OS to Date in ES-SCLC
Adding benmelstobart and anlotinib to first-line chemotherapy improved survival outcomes in a phase 3 trial of patients with ES-SCLC.
Adding Serplulimab to Chemotherapy Improves Survival in Squamous NSCLC
First-line treatment with serplulimab plus chemotherapy improves survival over chemotherapy alone in patients with advanced squamous NSCLC, a phase 3 trial suggests.
Regular Opioid Use May Increase the Risk of Lung Cancer
Researchers found that patients who used opioids regularly had a roughly 30% higher risk of lung cancer than patients who did not use opioids.
Genetic Predisposition to Lung Cancer May Be Greater in Women Than in Men
New research suggests that genetic susceptibility to lung cancer is greater in women, and a family history of cancer predicts lung cancer risk.
Iruplinalkib Outperforms Crizotinib in ALK+, Advanced NSCLC
Iruplinalkib, a novel ALK inhibitor, was more effective than crizotinib in a phase 3 trial of patients with advanced, ALK-positive non-small cell lung cancer.
Incidence of Lung Cancer Subtypes Varies by Region
Incidence rates of lung cancer subtypes vary across global regions, data suggest.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...